Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2007

01.12.2007 | Epidemiology

Genetic polymorphisms of NOS3 are associated with the risk of invasive breast cancer with lymph node involvement

verfasst von: Kyoung-Mu Lee, Ji-Yeob Choi, Jong Eun Lee, Dong-Young Noh, Sei-Hyun Ahn, Wonshik Han, Keun-Young Yoo, Richard B. Hayes, Daehee Kang

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2007

Einloggen, um Zugang zu erhalten

Abstract

Endothelial nitric oxide synthase (NOS3) produces nitric oxide which is a mediator of cytotoxic effects potentially associated with breast cancer. We evaluated the role of genetic polymorphisms of NOS3 in breast cancer etiology, in a case–control study conducted in Korea. We recruited 1,385 eligible patients with histologicaly confirmed incident breast cancer cases and 968 hospital-based controls. Two potentially functional NOS3 polymorphisms in the promoter region (−786T > C) and exon 7 (894G > T, Glu298Asp) were genotyped and individual haplotypes were estimated. Odds ratios (ORs) and 95% confidential intervals (95% CIs) were calculated by unconditional logistic regression, adjusting for age, body mass index, education, family history of breast cancer in first and second degree relatives, age at first full-term pregnancy and parity. There was no overall association between the −786T > C or 894G > T genotype and breast cancer risk. However, the −786C allele was marginally associated with decreased risk for invasive breast cancer with lymph node involvement (OR = 0.76, 95% CI = 0.56–1.04). And, compared to TG-TG carriers, all other haplotype pairs were significantly associated with invasive breast cancer with lymph node involvement (OR = 0.77, 95% CI = 0.59–0.99). Our results suggest that genetic polymorphisms in NOS3 modify individual susceptibility to invasive breast cancer with lymph node involvement in Korean women.
Literatur
1.
Zurück zum Zitat Loibl S, Buck A, Strank C, von Minckwitz G, Roller M, Sinn HP, Schini-Kerth V, Solbach C, Strebhardt K, Kaufmann M (2005) The role of early expression of inducible nitric oxide synthase in human breast cancer. Eur J Cancer 41(2):265–271PubMedCrossRef Loibl S, Buck A, Strank C, von Minckwitz G, Roller M, Sinn HP, Schini-Kerth V, Solbach C, Strebhardt K, Kaufmann M (2005) The role of early expression of inducible nitric oxide synthase in human breast cancer. Eur J Cancer 41(2):265–271PubMedCrossRef
2.
Zurück zum Zitat Thomsen LL, Miles DW (1998) Role of nitric oxide in tumour progression: lessons from human tumours. Cancer Metast Rev 17(1):107–118 CrossRef Thomsen LL, Miles DW (1998) Role of nitric oxide in tumour progression: lessons from human tumours. Cancer Metast Rev 17(1):107–118 CrossRef
3.
Zurück zum Zitat Lala PK, Orucevic A (1998) Role of nitric oxide in tumor progression: lessons from experimental tumors. Cancer Metast Rev 81:889–896 Lala PK, Orucevic A (1998) Role of nitric oxide in tumor progression: lessons from experimental tumors. Cancer Metast Rev 81:889–896
4.
Zurück zum Zitat Forstermann U, Boissel JP, Kleinert H (1998) Expressional control of the ‘constitutive’ isoforms of nitric oxide synthase (NOS I and NOS III). FASEB J 12(10):773–790 PubMed Forstermann U, Boissel JP, Kleinert H (1998) Expressional control of the ‘constitutive’ isoforms of nitric oxide synthase (NOS I and NOS III). FASEB J 12(10):773–790 PubMed
5.
Zurück zum Zitat Hingorani AD (2003) Endothelial nitric oxide synthase polymorphisms and hypertension. Curr Hypertens Rep 5(1):19–25PubMedCrossRef Hingorani AD (2003) Endothelial nitric oxide synthase polymorphisms and hypertension. Curr Hypertens Rep 5(1):19–25PubMedCrossRef
6.
Zurück zum Zitat Rao S, Austin H, Davidoff MN, Zafari AM (2005) Endothelial nitric oxide synthase intron 4 polymorphism is a marker for coronary artery disease in African–American and Caucasian men. Ethn Dis 15(2):191–197PubMed Rao S, Austin H, Davidoff MN, Zafari AM (2005) Endothelial nitric oxide synthase intron 4 polymorphism is a marker for coronary artery disease in African–American and Caucasian men. Ethn Dis 15(2):191–197PubMed
7.
Zurück zum Zitat Yoshimura T, Yoshimura M, Tabata A, Shimasaki Y, Nakayama M, Miyamoto Y, Saito Y, Nakao K, Yasue H, Okamura H (2000) Association of the missense Glu298Asp variant of the endothelial nitric oxide synthase gene with severe preeclampsia. J Soc Gynecol Investig 7(4):238–241PubMedCrossRef Yoshimura T, Yoshimura M, Tabata A, Shimasaki Y, Nakayama M, Miyamoto Y, Saito Y, Nakao K, Yasue H, Okamura H (2000) Association of the missense Glu298Asp variant of the endothelial nitric oxide synthase gene with severe preeclampsia. J Soc Gynecol Investig 7(4):238–241PubMedCrossRef
8.
Zurück zum Zitat Ntais C, Polycarpou A (2005) Association of the endothelial nitric oxide synthase (NOS3) Glu298Asp gene polymorphism with the risk of Alzheimer’s disease––a meta-analysis. J Neurol 252(10):1276–1278PubMedCrossRef Ntais C, Polycarpou A (2005) Association of the endothelial nitric oxide synthase (NOS3) Glu298Asp gene polymorphism with the risk of Alzheimer’s disease––a meta-analysis. J Neurol 252(10):1276–1278PubMedCrossRef
9.
Zurück zum Zitat Ghilardi G, Biondi ML, Cecchini F, DeMonti M, Guagnellini E, Scorza R (2003) Vascular invasion in human breast cancer is correlated to T786C polymorphism of NOS3 gene. Nitric Oxide 9(2):118–122PubMedCrossRef Ghilardi G, Biondi ML, Cecchini F, DeMonti M, Guagnellini E, Scorza R (2003) Vascular invasion in human breast cancer is correlated to T786C polymorphism of NOS3 gene. Nitric Oxide 9(2):118–122PubMedCrossRef
10.
Zurück zum Zitat Hefler LA, Ludwig E, Lampe D, Zeillinger R, Leodolter S, Gitsch G, Koelbl H, Tempfer CB (2002) Polymorphisms of the endothelial nitric oxide synthase gene in ovarian cancer. Gynecol Oncol 86(2):134–137PubMedCrossRef Hefler LA, Ludwig E, Lampe D, Zeillinger R, Leodolter S, Gitsch G, Koelbl H, Tempfer CB (2002) Polymorphisms of the endothelial nitric oxide synthase gene in ovarian cancer. Gynecol Oncol 86(2):134–137PubMedCrossRef
11.
Zurück zum Zitat Medeiros R, Morais A, Vasconcelos A, Costa S, Pinto D, Oliveira J, Lopes C (2002) Endothelial nitric oxide synthase gene polymorphisms and genetic susceptibility to prostate cancer. Eur J Cancer Prev 11(4):343–350PubMedCrossRef Medeiros R, Morais A, Vasconcelos A, Costa S, Pinto D, Oliveira J, Lopes C (2002) Endothelial nitric oxide synthase gene polymorphisms and genetic susceptibility to prostate cancer. Eur J Cancer Prev 11(4):343–350PubMedCrossRef
12.
Zurück zum Zitat Hefler LA, Grimm C, Lantzsch T, Lampe D, Koelbl H, Lebrecht A, Heinze G, Tempfer C, Reinthaller A, Zeillinger R (2006) Polymorphisms of the endothelial nitric oxide synthase gene in breast cancer. Breast Cancer Res Treat 98(2):151–155PubMedCrossRef Hefler LA, Grimm C, Lantzsch T, Lampe D, Koelbl H, Lebrecht A, Heinze G, Tempfer C, Reinthaller A, Zeillinger R (2006) Polymorphisms of the endothelial nitric oxide synthase gene in breast cancer. Breast Cancer Res Treat 98(2):151–155PubMedCrossRef
13.
Zurück zum Zitat Lu J, Wei Q, Bondy ML, Yu TK, Li D, Brewster A, Shete S, Sahin A, Meric-Bernstam F, Wang LE (2006) Promoter polymorphism (−786t > C) in the endothelial nitric oxide synthase gene is associated with risk of sporadic breast cancer in non-Hispanic white women age younger than 55 years. Cancer 107(9):2245–2253PubMedCrossRef Lu J, Wei Q, Bondy ML, Yu TK, Li D, Brewster A, Shete S, Sahin A, Meric-Bernstam F, Wang LE (2006) Promoter polymorphism (−786t > C) in the endothelial nitric oxide synthase gene is associated with risk of sporadic breast cancer in non-Hispanic white women age younger than 55 years. Cancer 107(9):2245–2253PubMedCrossRef
14.
Zurück zum Zitat Royo JL, Moreno-Nogueira JA, Galan JJ, Gonzalez-Martin A, Ruiz A, Gonzalez-Mancha R, Real LM (2006) Lack of association between NOS3 Glu298Asp and breast cancer risk: a case–control study. Breast Cancer Res Treat 100(3):331–333PubMedCrossRef Royo JL, Moreno-Nogueira JA, Galan JJ, Gonzalez-Martin A, Ruiz A, Gonzalez-Mancha R, Real LM (2006) Lack of association between NOS3 Glu298Asp and breast cancer risk: a case–control study. Breast Cancer Res Treat 100(3):331–333PubMedCrossRef
15.
Zurück zum Zitat Choi JY, Lee KM, Noh DY, Ahn SH, Lee JE, Han W, Jang IJ, Shin SG, Yoo KY, Hayes RB, Kang D (2006) Genetic polymorphisms of eNOS, hormone receptor status, and survival of breast cancer. Breast Cancer Res Treat 100(2):213–218PubMedCrossRef Choi JY, Lee KM, Noh DY, Ahn SH, Lee JE, Han W, Jang IJ, Shin SG, Yoo KY, Hayes RB, Kang D (2006) Genetic polymorphisms of eNOS, hormone receptor status, and survival of breast cancer. Breast Cancer Res Treat 100(2):213–218PubMedCrossRef
16.
Zurück zum Zitat Stephens M, Donnelly P (2003) A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 73:1162–1169PubMedCrossRef Stephens M, Donnelly P (2003) A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 73:1162–1169PubMedCrossRef
17.
Zurück zum Zitat Page GP, Amos CI (1999) Comparison of linkage-disequilibrium methods for localization of genes influencing quantitative traits in humans. Am J Hum Genet 64(4):1194–1205PubMedCrossRef Page GP, Amos CI (1999) Comparison of linkage-disequilibrium methods for localization of genes influencing quantitative traits in humans. Am J Hum Genet 64(4):1194–1205PubMedCrossRef
18.
Zurück zum Zitat Martin JH, Begum S, Alalami O, Harrison A, Scott KW (2000) Endothelial nitric oxide synthase: correlation with histologic grade, lymph node status and estrogen receptor expression in human breast cancer. Tumour Biol 21(2):90–97PubMedCrossRef Martin JH, Begum S, Alalami O, Harrison A, Scott KW (2000) Endothelial nitric oxide synthase: correlation with histologic grade, lymph node status and estrogen receptor expression in human breast cancer. Tumour Biol 21(2):90–97PubMedCrossRef
19.
Zurück zum Zitat Loibl S, Strank C, von Minckwitz G, Sinn HP, Buck A, Solbach C, Strebhardt K, Kaufmann M (2005) Immunohistochemical evaluation of endothelial nitric oxide synthase expression in primary breast cancer. Breast 14:230–235PubMedCrossRef Loibl S, Strank C, von Minckwitz G, Sinn HP, Buck A, Solbach C, Strebhardt K, Kaufmann M (2005) Immunohistochemical evaluation of endothelial nitric oxide synthase expression in primary breast cancer. Breast 14:230–235PubMedCrossRef
20.
Zurück zum Zitat Tanus-Santos JE, Desai M, Deak LR, Pezzullo JC, Abernethy DR, Flockhart DA, Freedman JE (2002) Effects of endothelial nitric oxide synthase gene polymorphisms on platelet function, nitric oxide release, and interactions with estradiol. Pharmacogenetics 12(5): 407–413PubMedCrossRef Tanus-Santos JE, Desai M, Deak LR, Pezzullo JC, Abernethy DR, Flockhart DA, Freedman JE (2002) Effects of endothelial nitric oxide synthase gene polymorphisms on platelet function, nitric oxide release, and interactions with estradiol. Pharmacogenetics 12(5): 407–413PubMedCrossRef
21.
Zurück zum Zitat Thomsen LL, Miles DW, Happerfield L, Bobrow LG, Knowles RG, Moncada S (1995) Nitric oxide synthase activity in human breast cancer. Br J Cancer 72(1):41–44PubMed Thomsen LL, Miles DW, Happerfield L, Bobrow LG, Knowles RG, Moncada S (1995) Nitric oxide synthase activity in human breast cancer. Br J Cancer 72(1):41–44PubMed
22.
Zurück zum Zitat Jadeski LC, Hum KO, Chakraborty C, Lala PK (2000) Nitric oxide promotes murine mammary tumour growth and metastasis by stimulating tumour cell migration, invasiveness and angiogenesis. Int J Cancer 86(1):30–39PubMedCrossRef Jadeski LC, Hum KO, Chakraborty C, Lala PK (2000) Nitric oxide promotes murine mammary tumour growth and metastasis by stimulating tumour cell migration, invasiveness and angiogenesis. Int J Cancer 86(1):30–39PubMedCrossRef
23.
Zurück zum Zitat Tse GM, Wong FC, Tsang AK, Lee CS, Lui PC, Lo AW, Law BK, Scolyer RA, Karim RZ, Putti TC (2005) Stromal nitric oxide synthase (NOS) expression correlates with the grade of mammary phyllodes tumour. J Clin Pathol 58(6):600–604PubMedCrossRef Tse GM, Wong FC, Tsang AK, Lee CS, Lui PC, Lo AW, Law BK, Scolyer RA, Karim RZ, Putti TC (2005) Stromal nitric oxide synthase (NOS) expression correlates with the grade of mammary phyllodes tumour. J Clin Pathol 58(6):600–604PubMedCrossRef
24.
Zurück zum Zitat Nakamura Y, Yasuoka H, Tsujimoto M, Yoshidome K, Nakahara M, Nakao K, Nakamura M, Kakudo K (2006) Nitric oxide in breast cancer: induction of vascular endothelial growth factor-C and correlation with metastasis and poor prognosis. Clin Cancer Res 12(4):1201–1207PubMedCrossRef Nakamura Y, Yasuoka H, Tsujimoto M, Yoshidome K, Nakahara M, Nakao K, Nakamura M, Kakudo K (2006) Nitric oxide in breast cancer: induction of vascular endothelial growth factor-C and correlation with metastasis and poor prognosis. Clin Cancer Res 12(4):1201–1207PubMedCrossRef
25.
Zurück zum Zitat Nakayama M, Yasue H, Yoshimura M, Shimasaki Y, Kugiyama K, Ogawa H, Motoyama T, Saito Y, Ogawa Y, Miyamoto Y, Nakao K (1999) T-786–>C mutation in the 5′-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation 99(22):2864–2870PubMed Nakayama M, Yasue H, Yoshimura M, Shimasaki Y, Kugiyama K, Ogawa H, Motoyama T, Saito Y, Ogawa Y, Miyamoto Y, Nakao K (1999) T-786–>C mutation in the 5′-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation 99(22):2864–2870PubMed
26.
Zurück zum Zitat Wang J, Dudley D, Wang XL (2002) Haplotype-specific effects on endothelial NO synthase promoter efficiency: modifiable by cigarette smoking. Arterioscler Thromb Vasc Biol 22(5):e1–e4PubMedCrossRef Wang J, Dudley D, Wang XL (2002) Haplotype-specific effects on endothelial NO synthase promoter efficiency: modifiable by cigarette smoking. Arterioscler Thromb Vasc Biol 22(5):e1–e4PubMedCrossRef
27.
Zurück zum Zitat Ahsan A, Norboo T, Baig MA, Qadar Pasha MA (2005) Simultaneous selection of the wild-type genotypes of the G894T and 4B/ 4A polymorphisms of NOS3 associate with high-altitude adaptation. Ann Hum Genet 69(Pt 3):260–267 PubMedCrossRef Ahsan A, Norboo T, Baig MA, Qadar Pasha MA (2005) Simultaneous selection of the wild-type genotypes of the G894T and 4B/ 4A polymorphisms of NOS3 associate with high-altitude adaptation. Ann Hum Genet 69(Pt 3):260–267 PubMedCrossRef
28.
Zurück zum Zitat Tesauro M, Thompson WC, Rogliani P, Qi L, Chaudhary PP, Moss J (2000) Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298. Proc Natl Acad Sci USA 97(6):2832–2835PubMedCrossRef Tesauro M, Thompson WC, Rogliani P, Qi L, Chaudhary PP, Moss J (2000) Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298. Proc Natl Acad Sci USA 97(6):2832–2835PubMedCrossRef
29.
Zurück zum Zitat Fairchild TA, Fulton D, Fontana JT, Gratton JP, McCabe TJ, Sessa WC (2001) Acidic hydrolysis as a mechanism for the cleavage of the Glu(298)→Asp variant of human endothelial nitric-oxide synthase. J Biol Chem 276(28):26674–26679PubMedCrossRef Fairchild TA, Fulton D, Fontana JT, Gratton JP, McCabe TJ, Sessa WC (2001) Acidic hydrolysis as a mechanism for the cleavage of the Glu(298)→Asp variant of human endothelial nitric-oxide synthase. J Biol Chem 276(28):26674–26679PubMedCrossRef
30.
Zurück zum Zitat Mortensen K, Holck S, Christensen IJ, Skouv J, Hougaard DM, Blom J, Larsson LI (1999) Endothelial cell nitric oxide synthase in peritumoral microvessels is a favorable prognostic indicator in premenopausal breast cancer patients. Clin Cancer Res 5(5):1093–1097PubMed Mortensen K, Holck S, Christensen IJ, Skouv J, Hougaard DM, Blom J, Larsson LI (1999) Endothelial cell nitric oxide synthase in peritumoral microvessels is a favorable prognostic indicator in premenopausal breast cancer patients. Clin Cancer Res 5(5):1093–1097PubMed
31.
Zurück zum Zitat Jadeski LC, Chakraborty C, Lala PK (2003) Nitric oxide-mediated promotion of mammary tumour cell migration requires sequential activation of nitric oxide synthase, guanylate cyclase and mitogen-activated protein kinase. Int J Cancer 106(4):496–504PubMedCrossRef Jadeski LC, Chakraborty C, Lala PK (2003) Nitric oxide-mediated promotion of mammary tumour cell migration requires sequential activation of nitric oxide synthase, guanylate cyclase and mitogen-activated protein kinase. Int J Cancer 106(4):496–504PubMedCrossRef
Metadaten
Titel
Genetic polymorphisms of NOS3 are associated with the risk of invasive breast cancer with lymph node involvement
verfasst von
Kyoung-Mu Lee
Ji-Yeob Choi
Jong Eun Lee
Dong-Young Noh
Sei-Hyun Ahn
Wonshik Han
Keun-Young Yoo
Richard B. Hayes
Daehee Kang
Publikationsdatum
01.12.2007
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2007
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-007-9506-y

Weitere Artikel der Ausgabe 3/2007

Breast Cancer Research and Treatment 3/2007 Zur Ausgabe

Preclinical Study/Clinical Trial/Epidemiology/Invited Commentary

G:C > A:T mutations and potential epigenetic regulation of p53 in breast cancer

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.